Avalyn PharmaAVLN
Recorded

Avalyn Pharma 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Seamus FernandezAnalyst

For joining us here at Guggenheim's Healthcare Innovation Conference. I'm really pleased to actually have Avalyn Pharma back with us again, but this year as a public company.

Seamus FernandezAnalyst

Woo-hoo. Thrilled to have Lyn Baranowski, CEO, to my right, and to her right, Doug Carlson, CFO and Chief Business Officer.

Seamus FernandezAnalyst

Thank you both for joining us.

Seamus FernandezAnalyst

Pleasure. As always, an exciting time to be talking about IPF and biotech.

Seamus FernandezAnalyst

Maybe just in terms of, just to kick us off, Lynn, maybe give us a quick background on Avalyn, what you're seeking to accomplish in IPF in particular.

Lyn BaranowskiCEO

Yeah, great. Thanks for the invitation and for being here to talk with us. Avalyn's a clinical-stage company. We're focused in pulmonary fibrosis. It is one of the rare deadly diseases in the lung space that just is massively unaddressed. What I mean by that is that we today have three drugs that are approved for the disease, two that have been on the market for about 10 years, and those two drugs are almost impossible for patients to tolerate. If you're on one of those two drugs or you're trying to be on one of those two drugs, you're going to have awful symptoms of the drug.

Lyn BaranowskiCEO

Horrible nausea and vomiting with one, horrible diarrhea with the other, and that's on top of the symptoms of this already quite horrible disease where you've got breathlessness, you've got cough, you can't get enough oxygen to get enough exercise capacity. Fundamentally, patients might try these oral medicines, but they cycle off medicine incredibly quickly because of the tolerability profile. What we're doing here at Avalyn is taking those same drugs that we know work, but now delivering them to the lung directly with an inhalation. When we do that, if you can imagine it, we're focusing our drug in the lung, which is the target organ, and we actually have better exposure in the lung, despite the fact that we're dropping the dose by more than tenfold as compared to the oral.

Lyn BaranowskiCEO

When you do that, you're also avoiding most of the systemic exposure that you'd have with the oral. We think this approach is much more sensible for patients because it takes the drugs that we know work, but now makes them significantly more tolerable, and we think more effective by delivering them to the lung directly. With that kind of profile, we now think it's going to be possible with these drugs, number one, to take patients that are diagnosed and treat them with these medicines, allow them to stay on medicine and benefit from the drugs now over a much longer term horizon. Fundamentally in this disease, we can talk about this, patients have been unable to combine mechanisms. We've learned in lung disease that we typically want to be combining different drugs together to do more for patients and their diseases.

Lyn BaranowskiCEO

That's impossible in this disease because each of the monotherapies is so impossible to tolerate. But resolving the tolerability with inhaled delivery allows us, we think, to help the market evolve in the algorithm towards one where we can start benefiting patients by dosing them in combination. We think that's going to be a massive change for this market. It's what the patients need, and I think we're the company to be able to deliver that.

Seamus FernandezAnalyst

Great. Let's talk about what is unique and novel about, I guess I'm saying the same thing twice, but what is unique about the approach with the device itself?

Seamus FernandezAnalyst

Not just the delivery program, but there's a choice of going after a nebulized product.

Seamus FernandezAnalyst

Yeah That I think is important.

Lyn BaranowskiCEO

Why, yeah. So when we think about delivering drugs to the lung with an inhalation, we obviously have to think about the drug itself and figure out how we can formulate it. Not all drugs are formulatable in all the different technologies that exist. We have to think about also the kind of particle size that we want to deliver. In this case, we want to deliver a really tiny particle that will get to the distal parts of the lung. The alveoli is the target tissue here. Not every nebulizer will be able to generate the right particle size to get there. Then we have to think about deeply the patients, and I think this is maybe what a lot of investors don't fully understand about this disease. These patients, as I said earlier, they're older, they're sick, they're frail, they have limited exercise capacity, they're breathless.

Lyn BaranowskiCEO

Some inhalers, like dry powder inhalers, require a patient to do this, which I can do because I've only got mild asthma. Normal asthmatic patients can do that, but this kind of patient isn't going to have that inhalation capacity. So our view is that this market and these patients are best served by figuring out an inhalation technology that the patients can actually dose. So this is a small handheld nebulizer. It's 510(k) approved. It's patent protected. We have a license to it. We have exclusivity in it in the molecules. The device is in our label. But from a patient perspective, this generates and delivers this really gentle mist. Sort of looks like if anyone ever had a humidifier when they were sick and their mom put it on when they were a kid.

Lyn BaranowskiCEO

It's very gentle and soft like that, and patients don't need to have any kind of a special breathing to be able to dose it. You just put it in your mouth and you breathe in and out using what we call tidal breathing, your normal breathing pattern.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day